209 related articles for article (PubMed ID: 15279586)
1. Recent advances in understanding the molecular mechanisms of HIV-1 entry and fusion: revisiting current targets and considering new options for therapeutic intervention.
Markovic I; Clouse KA
Curr HIV Res; 2004 Jul; 2(3):223-34. PubMed ID: 15279586
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.
Keller PW; Morrison O; Vassell R; Weiss CD
J Virol; 2018 Aug; 92(16):. PubMed ID: 29875245
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 gp41: mediator of fusion and target for inhibition.
Weiss CD
AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
[TBL] [Abstract][Full Text] [Related]
5. The HIV entry inhibitors revisited.
Leonard JT; Roy K
Curr Med Chem; 2006; 13(8):911-34. PubMed ID: 16611075
[TBL] [Abstract][Full Text] [Related]
6. Cellular entry of HIV: Evaluation of therapeutic targets.
Pöhlmann S; Reeves JD
Curr Pharm Des; 2006; 12(16):1963-73. PubMed ID: 16787241
[TBL] [Abstract][Full Text] [Related]
7. The current status and challenges in the development of fusion inhibitors as therapeutics for HIV-1 infection.
Tan JJ; Ma XT; Liu C; Zhang XY; Wang CX
Curr Pharm Des; 2013; 19(10):1810-7. PubMed ID: 23092283
[TBL] [Abstract][Full Text] [Related]
8. Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry.
Markovic I; Stantchev TS; Fields KH; Tiffany LJ; Tomiç M; Weiss CD; Broder CC; Strebel K; Clouse KA
Blood; 2004 Mar; 103(5):1586-94. PubMed ID: 14592831
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 Entry and Membrane Fusion Inhibitors.
Xiao T; Cai Y; Chen B
Viruses; 2021 Apr; 13(5):. PubMed ID: 33922579
[TBL] [Abstract][Full Text] [Related]
10. Virus entry as a target for anti-HIV intervention.
Esté JA
Curr Med Chem; 2003 Sep; 10(17):1617-32. PubMed ID: 12871111
[TBL] [Abstract][Full Text] [Related]
11. Advances in HIV-1 entry inhibitors: strategies to interfere with receptor and coreceptor engagement.
Markovic I
Curr Pharm Des; 2006; 12(9):1105-19. PubMed ID: 16515489
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 entry and its inhibition.
Pierson TC; Doms RW
Curr Top Microbiol Immunol; 2003; 281():1-27. PubMed ID: 12932074
[TBL] [Abstract][Full Text] [Related]
13. Progress in targeting HIV-1 entry.
Ryser HJ; Flückiger R
Drug Discov Today; 2005 Aug; 10(16):1085-94. PubMed ID: 16182193
[TBL] [Abstract][Full Text] [Related]
14. Capture of an early fusion-active conformation of HIV-1 gp41.
Furuta RA; Wild CT; Weng Y; Weiss CD
Nat Struct Biol; 1998 Apr; 5(4):276-9. PubMed ID: 9546217
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus type 1 Env with an intersubunit disulfide bond engages coreceptors but requires bond reduction after engagement to induce fusion.
Abrahamyan LG; Markosyan RM; Moore JP; Cohen FS; Melikyan GB
J Virol; 2003 May; 77(10):5829-36. PubMed ID: 12719576
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 Entry Inhibitors: A Review of Experimental and Computational Studies.
Mostashari Rad T; Saghaie L; Fassihi A
Chem Biodivers; 2018 Oct; 15(10):e1800159. PubMed ID: 30027572
[TBL] [Abstract][Full Text] [Related]
17. Potential drug targets on the HIV-1 envelope glycoproteins, gp120 and gp41.
Huang L; Zhang L; Chen CH
Curr Pharm Des; 2003; 9(18):1453-62. PubMed ID: 12769725
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015).
Li W; Lu L; Li W; Jiang S
Expert Opin Ther Pat; 2017 Jun; 27(6):707-719. PubMed ID: 28076686
[TBL] [Abstract][Full Text] [Related]
19. Emerging drug targets for antiretroviral therapy.
Reeves JD; Piefer AJ
Drugs; 2005; 65(13):1747-66. PubMed ID: 16114975
[TBL] [Abstract][Full Text] [Related]
20. Targeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapy.
Garg H; Viard M; Jacobs A; Blumenthal R
Curr Top Med Chem; 2011 Dec; 11(24):2947-58. PubMed ID: 22044225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
